Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.
Physician Information and Management Guidelines for Patients with Multiple Sclerosis receiving TYSABRI Therapy
This guidance document has been developed for those physicians initiating and supervising TYSABRI in accordance with the conditions of the Marketing Authorisation of the drug.
For Healthcare Professionals
This form should be read carefully before continuing TYSABRI treatment for more than 2 years.
This form should be read carefully before discontinuing treatment with TYSABRI.
This form should be read carefully before starting treatment with TYSABRI.